Carisoprodol Tablet
Product Images NDC 51525-5901

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Carisoprodol (NDC 51525-5901). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 01

Chemical structure of carisoprodol, the active ingredient in Carisoprodol 250 mg oral tablets by Mylan Pharmaceuticals Inc. The diagram shows the arrangement of atoms and bonds in the carisoprodol molecule.*

FDA Label Image

Image 02

Carisoprodol 250 mg Tablets, USP label showing a 100-tablet package by Wallace Pharmaceuticals. The label includes the NDC 51525-5901-1, with instructions to see the enclosed full prescribing information. It has a red and white design with regulatory information, barcode, and a symbol indicating Schedule IV controlled substance.*

FDA Label Image

Image 03

Carisoprodol 250 mg oral tablets packaging label by Mylan Pharmaceuticals Inc. The image shows a black oval logo with a white intertwined double helix design, commonly associated with the manufacturer branding. No dosage count or additional labeling is visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.